Proteome Sciences plc LON:PRM has received notification from Vulpes Life Sciences Fund that on 02 May 2017 it purchased 100,000 ordinary shares of 1p each in the capital of the Company at a price of 5p per Ordinary Share (the “Purchase”). Following the Purchase Vulpes has a total direct and indirect interest in 54,143,715 equivalent to 18.38% of Proteome Sciences’ total issued share capital.
The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 54,143,715 Ordinary Shares of the Company representing 18.38% of the issued share capital of the Company.
1. Details of the person discharging managerial responsibilities / person closely associated a) Name Vulpes Life Sciences Fund 2. Reason for the Notification a) Position/status PCA of Martin Diggle (NED) b) Initial notification/Amendment Initial notification 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Proteome Sciences plc b) LEI n/a 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the Financial instrument, type of Ordinary Shares of 1p each instrument Identification code GB0003104196 b) Nature of the transaction Purchase c) Price(s) and volume(s) 100,000 Ordinary Shares at 5p per Ordinary Shares d) Aggregated information: -- Aggregated volume 100,000 Ordinary Shares of 1p each purchased at a price -- Price of 5p per Ordinary Share e) Date of the transaction 2 May 2017 f) Place of the transaction London Stock Exchange, AIM Market (XLON)